Why the study?
What are the cardiovascular effects of therapeutic doses of tricyclic antidepressants in depressed patients?
What are the cardiovascular effects of therapeutic doses of tricyclic antidepressants in depressed patients?
Therapeutic doses of tricyclic antidepressants are generally safe in depressed patients without cardiovascular disease, but require caution regarding orthostatic hypotension and heart block in specific cardiac populations.
Answers are grounded in this paper and cite their sources.
Requires caution for orthostatic hypotension and heart block in bundle-branch disease; leaves open need for modern RCTs on TCA safety.
Overdoses of tricyclic antidepressants (TCAs) leave no doubt that TCA drugs at high concentrations have serious cardiac effects. It has been assumed that, to a lesser extent, these effects will occur at usual therapeutic concentration. Recent prospective, plasma-level-controlled studies have improved our understanding of these drugs and proved these assumptions to be inaccurate. The most common serious cardiovascular complication of most tricyclic drugs is orthostatic hypotension. Tricyclic antidepressants are essentially free of any other serious adverse effects in depressed patients without cardiovascular disease. In patients with preexisting bundle-branch disease, there is a risk of heart block. On the other hand, patients with ventricular arrhythmias are likely to have their arrhythmias improve with TCA therapy. Finally, therapeutic doses of TCA have little adverse effect on left ventricular performance, but at least with imipramine there is a dramatic increase in orthostatic hypotension in those patients with impaired left ventricular function. Understanding these principles, TCA drugs can often be used to benefit depressed patients with overt heart disease.
No takes yet. Share an insight, caveat, or question.
A H Glassman (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: